{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:07:59Z","timestamp":1762459679810},"reference-count":28,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-na\u00efve neovascular age-related macular degeneration (nAMD) in Japan and the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Phase 2, multicenter, randomized, double-masked, 20-week studies (BAMBOO, Japan; CYPRESS, United States). Patients (n = 25 each study) received three monthly intravitreal injections of abicipar 1 mg or 2 mg or five monthly intravitreal injections of ranibizumab 0.5 mg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Mean best-corrected visual acuity change from baseline at week 16 (primary endpoint) for abicipar 1 mg, abicipar 2 mg, and ranibizumab was +7.8 letters, +8.9 letters, and +17.4 letters (BAMBOO); +4.4 letters, +10.1 letters, and +15.2 letters (CYPRESS). Mean central retinal thickness change from baseline was \u2212187.3 \u03bcm, \u2212196.5 \u03bcm, and \u2212230.4 \u03bcm (BAMBOO); \u2212106.5 \u03bcm, \u2212112.8 \u03bcm, and \u2212124.4 \u03bcm (CYPRESS). Uveitis or vitritis was reported in three abicipar-treated patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Abicipar demonstrated extended duration of effect and safety that were comparable between Japanese and non-Japanese patients with nAMD. Abicipar effectively treated Japanese patients with polypoidal choroidal vasculopathy.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>Ophthalmic Surg Lasers Imaging Retina.<\/jats:italic>\n                2019;50:e10\u2013e22.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/23258160-20190129-13","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T16:38:04Z","timestamp":1550248684000},"source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Patients With Neovascular Age-Related Macular Degeneration: Studies in Japan and the United States"],"prefix":"10.3928","volume":"50","author":[{"given":"Derek","family":"Kunimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Ohji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj K.","family":"Maturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"For the BAMBOO and CYPRESS Study Groups","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"doi-asserted-by":"publisher","key":"e_1_3_2_2_2","DOI":"10.1101\/cshperspect.a017178"},{"doi-asserted-by":"publisher","key":"e_1_3_2_3_2","DOI":"10.1136\/bjophthalmol-2014-305702"},{"doi-asserted-by":"publisher","key":"e_1_3_2_4_2","DOI":"10.1056\/NEJMoa062655"},{"doi-asserted-by":"publisher","key":"e_1_3_2_5_2","DOI":"10.1056\/NEJMoa054481"},{"doi-asserted-by":"publisher","key":"e_1_3_2_6_2","DOI":"10.1016\/j.ophtha.2010.12.019"},{"doi-asserted-by":"publisher","key":"e_1_3_2_7_2","DOI":"10.1016\/j.ophtha.2011.12.016"},{"doi-asserted-by":"publisher","key":"e_1_3_2_8_2","DOI":"10.1136\/bjophthalmol-2015-308074"},{"doi-asserted-by":"publisher","key":"e_1_3_2_9_2","DOI":"10.1159\/000431000"},{"doi-asserted-by":"publisher","key":"e_1_3_2_10_2","DOI":"10.1016\/j.preteyeres.2016.04.002"},{"doi-asserted-by":"publisher","key":"e_1_3_2_11_2","DOI":"10.1038\/eye.2016.71"},{"doi-asserted-by":"publisher","key":"e_1_3_2_12_2","DOI":"10.1016\/j.ajo.2012.09.032"},{"doi-asserted-by":"publisher","key":"e_1_3_2_13_2","DOI":"10.1016\/j.ajo.2014.05.037"},{"doi-asserted-by":"publisher","key":"e_1_3_2_14_2","DOI":"10.2174\/1871523016666170502115816"},{"doi-asserted-by":"publisher","key":"e_1_3_2_15_2","DOI":"10.1007\/s10456-011-9249-6"},{"doi-asserted-by":"publisher","key":"e_1_3_2_16_2","DOI":"10.1016\/j.ajo.2012.03.047"},{"doi-asserted-by":"publisher","key":"e_1_3_2_17_2","DOI":"10.1089\/jop.2018.0062"},{"doi-asserted-by":"publisher","key":"e_1_3_2_18_2","DOI":"10.1016\/j.ajo.2007.03.047"},{"doi-asserted-by":"publisher","key":"e_1_3_2_19_2","DOI":"10.1016\/S0197-2456(99)00031-8"},{"doi-asserted-by":"publisher","key":"e_1_3_2_20_2","DOI":"10.1016\/j.ophtha.2012.09.006"},{"doi-asserted-by":"publisher","key":"e_1_3_2_21_2","DOI":"10.1001\/archopht.125.11.1460"},{"doi-asserted-by":"publisher","key":"e_1_3_2_22_2","DOI":"10.1016\/j.ophtha.2009.09.002"},{"doi-asserted-by":"publisher","key":"e_1_3_2_23_2","DOI":"10.1016\/j.ajo.2013.12.018"},{"doi-asserted-by":"publisher","key":"e_1_3_2_24_2","DOI":"10.2147\/OPTH.S101596"},{"doi-asserted-by":"publisher","key":"e_1_3_2_25_2","DOI":"10.1089\/jop.2016.0098"},{"key":"e_1_3_2_26_2","first-page":"2355","article-title":"Aflibercept: A review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration","volume":"9","author":"Balaratnasingam C","year":"2015","unstructured":"Balaratnasingam C, Dhrami-Gavazi E, McCann JT, Ghadiali Q, Freund KB. Aflibercept: A review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol. 2015;9:2355\u20132371.","journal-title":"Clin Ophthalmol"},{"doi-asserted-by":"publisher","key":"e_1_3_2_27_2","DOI":"10.1186\/s12886-015-0026-y"},{"doi-asserted-by":"publisher","key":"e_1_3_2_28_2","DOI":"10.3341\/kjo.2012.26.3.157"},{"doi-asserted-by":"publisher","key":"e_1_3_2_29_2","DOI":"10.1016\/j.ajo.2016.02.019"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/23258160-20190129-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T04:45:54Z","timestamp":1683089154000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20190129-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.3928\/23258160-20190129-13"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20190129-13","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"type":"print","value":"2325-8160"},{"type":"electronic","value":"2325-8179"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}